Advertisement

HPV and HPV Vaccination Knowledge and Attitudes Among Medical Students in Alabama

  • Casey L. DanielEmail author
  • Lane McLendon
  • Chelsea L. Green
  • Katie J. Anderson
  • Jennifer Y. Pierce
  • Allen Perkins
  • Mark Beasley
Article
  • 13 Downloads

Abstract

In addition to being the most common sexually transmitted infection, the human papillomavirus (HPV) is associated with six types of cancer in men and women. The HPV vaccine provides long-lasting, effective protection from high-risk HPV infection, thus serving as a means of cancer prevention. An effective healthcare provider recommendation is well-established as the most significant influence on HPV vaccine uptake, and, as emerging providers, it is critical that medical students receive comprehensive training in this area. However, the type and extent of such training for current medical students in the USA is unclear. An online survey assessing HPV and HPV vaccine knowledge, attitudes, and vaccine status was distributed to all medical students at an Alabama university. Scales were developed to assess composite HPV and HPV knowledge scores and HPV vaccination intentions. Of those age-eligible, 32.1% reported completion of the HPV vaccine series while 15.2% reported partial completion. Knowledge of both HPV and HPV vaccination significantly increased with program year (p < 0.0001 and p = 0.0069, respectively); however, there were knowledge gaps across all years regarding HPV-associated cancers. Attitudes and intentions showed a similar association, with more advanced students demonstrating more positive attitudes toward HPV vaccination (p = 0.0003). There is a need within the current curriculum to include more education and training on HPV, HPV vaccination, and counseling—particularly for students in the first 2 years of their program. Implementation of a classroom module or interactive workshop would likely improve knowledge and attitudes, better preparing students for their future role as potential immunizers.

Keywords

HPV Human papillomavirus Medical education Student Vaccination 

Notes

Acknowledgments

Research support was provided by the Abraham A. Mitchell Clinical Cancer Research Award.

Compliance with Ethical Standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Approval for this study was gained through the Institutional Review Board at the University of South Alabama and informed consent was obtained from all individual participants included in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6(4):204CrossRefGoogle Scholar
  2. 2.
    HPV and cancer: statistics. https://www.cdc.gov/cancer/hpv/statistics/index.htm. Accessed 8 July 2019
  3. 3.
    Meites E, Kempe A, Markowitz LE (2016) Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 65(49):1405–1408CrossRefGoogle Scholar
  4. 4.
    Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A (2017) Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 390(10108):2143–2159CrossRefGoogle Scholar
  5. 5.
    Van Damme P, Meijer C, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M (2016) A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine 34(35):4205–4212CrossRefGoogle Scholar
  6. 6.
    Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S (2018) National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2017. MMWR Morb Mortal Wkly Rep 67(33):909–917CrossRefGoogle Scholar
  7. 7.
    Swiecki-Sikora AL, Henry KA, Kepka D (2019) HPV vaccination coverage among US teens across the rural-urban continuum. J Rural HealthGoogle Scholar
  8. 8.
    Warner EL, Ding Q, Pappas LM, Henry K, Kepka D (2017) White, affluent, educated parents are least likely to choose HPV vaccination for their children: a cross-sectional study of the National Immunization Study - teen. BMC Pediatr 17(1):200CrossRefGoogle Scholar
  9. 9.
    Cartmell KB, Young-Pierce J, McGue S, Alberg AJ, Luque JS, Zubizarreta M, Brandt HM (2018) Barriers, facilitators, and potential strategies for increasing HPV vaccination: a statewide assessment to inform action. Papillomavirus Res 5:21–31CrossRefGoogle Scholar
  10. 10.
    Dilley SE, Peral S, Straughn JM Jr, Scarinci IC (2018) The challenge of HPV vaccination uptake and opportunities for solutions: lessons learned from Alabama. Prev Med 113:124–131CrossRefGoogle Scholar
  11. 11.
    Gilkey MB, McRee AL (2016) Provider communication about HPV vaccination: a systematic review. Hum Vaccin Immunother 12(6):1454–1468CrossRefGoogle Scholar
  12. 12.
    Gerend MA, Shepherd MA, Lustria ML, Shepherd JE (2016) Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross-sectional survey. Sex Transm Infect 92(2):104–107CrossRefGoogle Scholar
  13. 13.
    Smith PJ, Stokley S, Bednarczyk RA, Orenstein WA, Omer SB (2016) HPV vaccination coverage of teen girls: the influence of health care providers. Vaccine 34(13):1604–1610CrossRefGoogle Scholar
  14. 14.
    McCusker SM, Macqueen I, Lough G, Macdonald AI, Campbell C, Graham SV (2013) Gaps in detailed knowledge of human papillomavirus (HPV) and the HPV vaccine among medical students in Scotland. BMC Public Health 13:264CrossRefGoogle Scholar
  15. 15.
    Voidazan S, Morariu SH, Tarcea M, Moldovan H, Curticapian I, Dobreanu M (2016) Human papillomavirus (HPV) infection and HPV vaccination: assessing the level of knowledge among students of the University of Medicine and Pharmacy of Tirgu Mures, Romania. Acta dermatovenerol Croatica : ADC 24(3):193–202Google Scholar
  16. 16.
    Wen Y, Pan XF, Zhao ZM, Chen F, Fu CJ, Li SQ, Zhao Y, Chang H, Xue QP, Yang CX (2014) Knowledge of human papillomavirus (HPV) infection, cervical cancer, and HPV vaccine and its correlates among medical students in Southwest China: a multi-center cross-sectional survey. Asian Pac J Cancer Prev : APJCP 15(14):5773–5779CrossRefGoogle Scholar
  17. 17.
    Shetty S, Prabhu S, Shetty V, Shetty AK (2019) Knowledge, attitudes and factors associated with acceptability of human papillomavirus vaccination among undergraduate medical, dental and nursing students in South India. Hum Vaccines Immunother:1–10Google Scholar
  18. 18.
    Afonso NM, Kavanagh MJ, Swanberg SM, Schulte JM, Wunderlich T, Lucia VC (2017) Will they lead by example? Assessment of vaccination rates and attitudes to human papilloma virus in millennial medical students. BMC Public Health 17(1):35CrossRefGoogle Scholar
  19. 19.
    Berenson AB, Hirth JM, Fuchs EL (2017) US medical students’ willingness to offer the HPV vaccine by vaccination status. Vaccine 35(9):1212–1215CrossRefGoogle Scholar
  20. 20.
    Evans L, Matley E, Oberbillig M, Margetts E, Darrow L (2019) HPV knowledge and attitudes among medical and professional students at a Nevada University: a focus on oropharyngeal cancer and mandating the vaccine. Journal of cancer education : the official journal of the American Association for Cancer EducationGoogle Scholar
  21. 21.
    Wiley R, Shelal Z, Urbauer D, Bernard C, Ramondetta L (2019) Relationship between intent to vaccinate and the education and knowledge of human papillomavirus among medical school faculty and students in Texas. Tex Med 115(1):e1Google Scholar
  22. 22.
    Vadaparampil ST, Kahn JA, Salmon D, Lee JH, Quinn GP, Roetzheim R, Bruder K, Malo TL, Proveaux T, Zhao X, Halsey N, Giuliano AR (2011) Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine 29(47):8634–8641CrossRefGoogle Scholar
  23. 23.
    Gilkey MB, Moss JL, Coyne-Beasley T, Hall ME, Shah PD, Brewer NT (2015) Physician communication about adolescent vaccination: how is human papillomavirus vaccine different? Prev Med 77:181–185CrossRefGoogle Scholar
  24. 24.
    Hswen Y, Gilkey MB, Rimer BK, Brewer NT (2017) Improving physician recommendations for human papillomavirus vaccination: the role of professional organizations. Sex Transm Dis 44(1):42–47CrossRefGoogle Scholar
  25. 25.
    Lake PW, Kasting ML, Christy SM, Vadaparampil ST (2019) Provider perspectives on multilevel barriers to HPV vaccination. Human vaccines & immunotherapeutics:1–10Google Scholar
  26. 26.
  27. 27.
    Schnaith AM, Evans EM, Vogt C, Tinsay AM, Schmidt TE, Tessier KM, Erickson BK (2018) An innovative medical school curriculum to address human papillomavirus vaccine hesitancy. Vaccine 36(26):3830–3835CrossRefGoogle Scholar
  28. 28.

Copyright information

© American Association for Cancer Education 2019

Authors and Affiliations

  1. 1.University of South Alabama College of MedicineMobileUSA
  2. 2.University of South Alabama Mitchell Cancer InstituteMobileUSA
  3. 3.University of Alabama at Birmingham Ryals School of Public HealthBirminghamUSA

Personalised recommendations